# Eaderm Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eaderm-co

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.eaderm.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Jun 17, 2025)
- Investors on record: 3

## About

Based in Tokyo, Japan, and founded in 2017, Ederm Co., Ltd. operates as a biotechnology company engaged in the research and development of therapeutic drugs through stem cell control for patients suffering from skin and hair diseases such as alopecia. In July 2023, Eaderm raised JPY 50 million in seed funding from ANRI. As of August 2023, the company is led by its representative director, Nobuhiro Ando.

Ederm Co., Ltd. develops therapeutic drugs that provide evidence-based solutions for ailments related to skin and hair health. Its stem cells, pivotal for maintaining healthy skin and hair, can deteriorate due to a variety of factors, leading to various diseases. The company's research focuses on identifying tissue stem cell pools and substances that preserve their quality and developing therapeutic drugs and quasi-drugs that promote both healthy regeneration and disease alleviation.

The company plans to use the seed funding to accelerate the development of its therapeutic drugs.

## Funding rounds

- Series A, Jun 17, 2025, $3.2M — ANRI, UntroD Capital, Rohto Pharmaceutical
- Seed, Jul 24, 2023, $0.3M — ANRI

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Seed, Series A
- UntroD Capital — Series A
- Rohto Pharmaceutical — Series A